Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

AVR vs FEMY: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

AVR Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 4–3 Matrix Metrics)

AVR Overall Winner 6-Pillar Tally: AVR 4 – 1 FEMY (1 Tie) Matrix Metrics: AVR 4 – 3 FEMY

As of Nov 16, 2026, Anteris Technologies Global Corp. (AVR) is the stronger overall head-to-head candidate over Femasys Inc. (FEMY) in the Tradestie Institutional Equity Comparison Engine, winning 4–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). AVR carries a Unified Composite Score of 48.2/100 (HOLD) at $5.70 (N/M Forward P/E, -4880.4% operating margin), whereas FEMY carries 52.6/100 (HOLD) at $1.28 (N/M Forward P/E, -763.9% operating margin).

  • Composite vs. Pillar Nuance: While FEMY currently prints a higher short-term Unified Composite Score (52.6/100 HOLD vs. AVR 48.2/100 HOLD), AVR captures the overall institutional head-to-head verdict (4–3 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-4880.4% vs. -763.9% operating margin) and revenue trajectory (+21.0% vs. -18.9% YoY).
  • Technical & Structure Timing Caution: AVR is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 42.5); meanwhile FEMY is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 34.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About AVR vs FEMY
AVR NASDAQ Head-to-Head Winner
Anteris Technologies Global Corp. Common Stock
Orthopedic, Prosthetic & Surgical Appliances & Supplies
$5.70
+5.17% 1D
Market Cap $528.4M
TTM Revenue $2.3M
Forward P/E N/M
Beta / 30D Vol 1.56β · 77% Vol
Unified Composite Score
48.2 / 100 HOLD
Tech 58.0 Fund 49.0 Flow 57.0 Mom 68.9
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -15.2%), weak momentum, RSI 42
RSI-14: 42.5 · SMA20: $5.93 · SMA50: $6.90
FEMY NASDAQ
Femasys Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$1.28
-9.86% 1D
Market Cap $11.9M
TTM Revenue $2.3M
Forward P/E N/M
Beta / 30D Vol 4.01β · 72% Vol
Unified Composite Score
52.6 / 100 HOLD
Tech 61.0 Fund 62.0 Flow 50.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -21.5%), weak momentum, RSI 35
RSI-14: 34.6 · SMA20: $1.43 · SMA50: $1.92

6-Pillar Scorecard Institutional Category Breakdown (AVR 4 – 1 FEMY)

Columns: Metric · AVR · FEMY
1. Valuation Multiples FEMY
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 133.9x 4.9x
2. Growth & Scale AVR
Revenue Growth (YoY) +21.0% -18.9%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $2.3M $2.3M
Market Cap $528.4M $11.9M
3. Profitability & Quality AVR
Gross Margin 75.8% 60.9%
Operating Margin -4880.4% -763.9%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -93.3% -425.0%
4. Balance Sheet & Cash Flow AVR
Cash Generation (TTM) -$94M -$19M
Cash Flow Margin N/A N/A
Net Cash / Leverage $216M Net Cash -$658,045 Net Debt (0.65x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning AVR
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 58.5% (52nd %ile) N/A (N/A)
Put/Call OI Skew 0.66x (Call-Skewed) N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Medical Instruments & Supplies Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: AVR (4) vs FEMY (3)
Institutional Metric AVR FEMY Criterion Row Edge
Market Capitalization
Scale
$528.4M $11.9M Larger Scale AVR
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+21.0% -18.9% Higher Growth AVR
Operating Margin (TTM)
Profitability
-4880.4% -763.9% Higher Margin FEMY
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-93.3% -425.0% Higher ROE AVR
52-Week Range Position
Momentum
31% ($3–$11) 17% ($0–$6) Stronger Trend AVR
Beta / 30D Volatility
Risk Regime
1.56β · 77% Vol 4.01β · 72% Vol Lower Realized Risk FEMY
Unified Institutional Score
Composite Signal
48.2 / 100 (HOLD) 52.6 / 100 (HOLD) Higher Composite FEMY
Trailing 12M Revenue (USD)
Operating Scale
$2.3M $2.3M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
75.8% 60.9% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 133.9x EV/Rev N/M PEG · 4.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$94M ($216M Net Cash) -$19M (-$658,045 Net Debt (0.65x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon AVR +16.63 pp
AVR: -5.79% · FEMY: -22.42%
3M Horizon AVR +1.32 pp
AVR: -40.5% · FEMY: -41.82%
6M Horizon FEMY +277.51 pp
AVR: -24.7% · FEMY: +252.81%
1Y Horizon FEMY +4.38 pp
AVR: +50.4% · FEMY: +54.78%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period AVR Revenue FEMY Revenue AVR Op. Margin FEMY Op. Margin Margin Leader
FY2020 N/A $0M N/A -668.0% FEMY
FY2021 N/A $0M N/A -706.7% FEMY
FY2022 N/A $0M N/A -961.7% FEMY
FY2023 N/A $0M N/A -1353.4% FEMY
FY2024 $0M $0M -2899.4% -1091.8% FEMY
FY2025 $0M $0M -4908.2% -767.0% FEMY

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
AVR BREAKDOWN
101d in phase · OBV NEUTRAL
Current IV 58.5%
IV Percentile 52nd %ile
Put/Call OI Skew 0.66x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow NEUTRAL
Exact AVR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
FEMY UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact FEMY Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
AVR Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $528.4M market capitalization and -4880.4% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
FEMY Moat Profile Cyclical / Execution-Driven Positioning
Medical Instruments & Supplies Operator
Competes within the Medical Instruments & Supplies value chain with $11.9M market capitalization and -763.9% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ AVR vs FEMY Key Questions & Quantitative Answers

As of Nov 16, 2026, Anteris Technologies Global Corp. (AVR) is the stronger overall head-to-head candidate over Femasys Inc. (FEMY) in the Tradestie Institutional Equity Comparison Engine, winning 4–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). AVR carries a Unified Composite Score of 48.2/100 (HOLD) at $5.70 (N/M Forward P/E, -4880.4% operating margin), whereas FEMY carries 52.6/100 (HOLD) at $1.28 (N/M Forward P/E, -763.9% operating margin). Composite vs. Pillar Nuance: While FEMY currently prints a higher short-term Unified Composite Score (52.6/100 HOLD vs. AVR 48.2/100 HOLD), AVR captures the overall institutional head-to-head verdict (4–3 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-4880.4% vs. -763.9% operating margin) and revenue trajectory (+21.0% vs. -18.9% YoY). Technical & Structure Timing Caution: AVR is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 42.5); meanwhile FEMY is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 34.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

AVR leads the Growth & Scale pillar: AVR posts +21.0% YoY revenue growth and +0.0% YoY earnings growth on $2.3M TTM revenue (75.8% gross margin, -4880.4% operating margin), compared with FEMY at -18.9% YoY revenue growth and +0.0% YoY earnings growth on $2.3M TTM revenue (60.9% gross margin, -763.9% operating margin). Across the 6-period historical trajectory (FY2020 to FY2025), AVR cumulative revenue shifted N/A while FEMY shifted N/A. In operating R&D and SG&A reinvestment, AVR deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for FEMY.

FEMY screens cheaper on headline valuation multiples. AVR trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 133.9x EV/Revenue (unreported FCF margin), whereas FEMY trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 4.9x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AVR (-93.3% ROE) versus FEMY (-425.0% ROE) capital efficiency.

In options market volatility and institutional positioning, AVR carries 58.5% implied volatility (52nd %ile, Balanced (25th–60th %ile)), a 0.66x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.56β · 77% Vol realized risk). By comparison, FEMY carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (4.01β · 72% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.